Tadalafil product-specific bioequivalence guidance

  • Email
  • Help
Current effective version

Revision 1 - Adopted guideline

Reference numberEMA/CHMP/315234/2014 Rev.1
Published01/02/2018
Effective from01/02/2018
KeywordsBioequivalence, generics, tadalafil
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of tadalafil.
Abbreviations
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
  • Cmax: maximum plasma concentration


Document history

Revision 1

 

Adopted guideline

 

Overview of comments

 

Draft guideline

In operation:01/08/2018-present

 

Published: 01/02/2018 

 

Published: 03/08/2017

First version

Current version

Adopted guideline


Overview of comments


Draft guideline

In operation: 01/12/2015–present


 Published: 07/07/2015


 Published: 15/11/2013


Related content


 

How helpful is this page?

Average rating:

 Based on 10 ratings

Add your rating:

See all ratings
2 ratings
2 ratings
2 ratings
2 ratings
2 ratings
    

Tell us more